Anaplastic lymphoma kinase as a therapeutic target

Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC).

(2017) Y. Bang et al.   JOURNAL OF CLINICAL ONCOLOGY

Small non-mucinous bronchioloalveolar carcinoma with anaplastic lymphoma kinase immunoreactivity: A novel ALK fusion gene?

(2012) Morio Yamamoto et al.   CANCER SCIENCE

Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer

(2012) Robert C. Doebele et al.   CLINICAL CANCER RESEARCH

Promising Therapeutic Targets in Neuroblastoma

(2012) K. K. Matthay et al.   CLINICAL CANCER RESEARCH

Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer

(2012) Sai-Hong Ignatius Ou   Expert Review of Anticancer Therapy

Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing

(2012) Yeonjoo Jung et al.   GENES CHROMOSOMES & CANCER

Abstract A243: Characterization of NMS-E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK-dependent lymphoma and non-small cell lung cancer models

(2012) E. Ardini et al.   MOLECULAR CANCER THERAPEUTICS

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

(2012) Doron Lipson et al.   NATURE MEDICINE

Treating ALK-positive lung cancer—early successes and future challenges

(2012) D. Ross Camidge et al.   Nature Reviews Clinical Oncology

KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only

(2012) Yuki Togashi et al.   PLoS One

Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance

(2012) C. M. Lovly et al.   Science Translational Medicine

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

(2012) R. Katayama et al.   Science Translational Medicine

CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant

(2011) Hiroshi Sakamoto et al.   CANCER CELL

Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors

(2011) C. M. Lovly et al.   CANCER RESEARCH

Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene

(2011) A. K. Murugan et al.   CANCER RESEARCH

Anaplastic lymphoma kinase–positive large B-cell lymphoma with complex karyotype and novel ALK gene rearrangements

(2011) Min Shi et al.   HUMAN PATHOLOGY

Anaplastic lymphoma kinase in human cancer

(2011) Antonella Barreca et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment

(2011) E. Grande et al.   MOLECULAR CANCER THERAPEUTICS

Crizotinib in Anaplastic Large-Cell Lymphoma

(2011) Carlo Gambacorti-Passerini et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models

(2011) E Normant et al.   ONCOGENE

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK

(2011) R. Katayama et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain

(2010) Christian C. Lee et al.   BIOCHEMICAL JOURNAL

Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia

(2010) S. Giuriato et al.   BLOOD

The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers

(2010) T. Sasaki et al.   CANCER RESEARCH

Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene

(2010) Z. Chen et al.   CANCER RESEARCH

Inhibitors of anaplastic lymphoma kinase: a patent review

(2010) Karen L Milkiewicz et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer

(2010) Marta Salido et al.   Journal of Thoracic Oncology

Renal cell carcinoma with novel VCL–ALK fusion: new representative of ALK-associated tumor spectrum

(2010) Larisa V Debelenko et al.   MODERN PATHOLOGY

Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor

(2010) James E. Butrynski et al.   NEW ENGLAND JOURNAL OF MEDICINE

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sonic Hedgehog Signaling Pathway Is Activated in ALK-Positive Anaplastic Large Cell Lymphoma

(2009) R. R. Singh et al.   CANCER RESEARCH

KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer

(2009) K. Takeuchi et al.   CLINICAL CANCER RESEARCH

Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy

(2009) Thomas R Webb et al.   Expert Review of Anticancer Therapy

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY

Anaplastic Lymphoma Kinase–Positive Diffuse Large B-Cell Lymphoma: A Rare Clinicopathologic Entity With Poor Prognosis

(2009) Camille Laurent et al.   JOURNAL OF CLINICAL ONCOLOGY

Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non-Small Cell Lung Cancers

(2009) E. Lin et al.   MOLECULAR CANCER RESEARCH

ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy

(2008) J. K. C. Chan et al.   BLOOD

Identification of ALK as a major familial neuroblastoma predisposition gene

(2008) Yaël P. Mossé et al.   NATURE

Oncogenic mutations of ALK kinase in neuroblastoma

(2008) Yuyan Chen et al.   NATURE

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

(2008) Isabelle Janoueix-Lerosey et al.   NATURE